XTNTHIGH SIGNALFINANCIAL10-K

XTNT achieved a dramatic financial turnaround with operating income swinging from -$12.1M to +$7.3M, but revenue declined 17.5% and the company signals significant headwinds from losing $18.7M in non-recurring license revenue.

The company experienced an exceptional operational transformation, moving from substantial losses to profitability while dramatically improving cash flow and reducing debt by 50%. However, this performance was bolstered by $18.7M in license revenue that management explicitly states will not repeat in 2026, creating uncertainty about the sustainability of this turnaround.

Comparing 2026-03-31 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

XTNT delivered a remarkable financial transformation despite declining revenues, with operating cash flow surging from -$11.9M to +$12.5M and the company achieving profitability after significant prior losses. The balance sheet strengthened considerably with cash nearly tripling to $17.1M, debt cut in half to $11.0M, and stockholders' equity growing 18.6%. However, the 17.5% revenue decline combined with management's warning about losing substantial non-recurring license revenue in 2026 raises questions about whether this impressive turnaround can be sustained.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+205.5%
-$11.9M→$12.5M

Operating cash flow surged 205.5% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+175.1%
$6.2M→$17.1M

Cash position surged 175.1% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
+160.3%
-$12.1M→$7.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+130.2%
-$16.4M→$5.0M

Net income grew 130.2% — bottom-line growth signals improving overall business health.

Total Debt
Balance Sheet
-50%
$22.0M→$11.0M

Debt reduced 50% — deleveraging strengthens balance sheet and reduces financial risk.

Capital Expenditure
Cash Flow
-42.1%
$4.1M→$2.4M

Capex reduced 42.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Gross Profit
P&L
+23.5%
$68.2M→$84.3M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Inventory
Balance Sheet
-21.7%
$38.6M→$30.3M

Inventory reduced 21.7% — lean inventory management or demand outpacing supply.

Stockholders Equity
Balance Sheet
+18.6%
$43.0M→$51.0M

Equity base grew 18.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
-17.5%
$64.7M→$53.3M

Revenue softened 17.5% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-06
ADDED
In addition, Xtant s biologics are utilized in trauma, foot and ankle, sports medicine, total joint, along with several surgical repair and wound care applications.
While our focus is the United States market, we promote and sell our products internationally through stocking distribution partners in Europe, Canada, Mexico, South America, and certain Pacific region countries.
We have recently made and intend to continue to make measured and targeted investments in the expansion of our commercial team to support our new products and maximize the reach of our broad portfolio of orthobiologics solutions.
Since one of our key growth initiatives is to leverage our growth platform with technology and strategic acquisitions and explore other strategic transactions with respect to our products and our company, including licenses, business collaborations and other business combinations or transactions with other companies, we, as a matter of course, often engage in discussions with third parties regarding such matters.
As discussed in more detail elsewhere in this report, we recognized $18.7 million in license revenue in 2025 that likely will not repeat in 2026 due primarily to changes in the reimbursement environment for our SimpliMax product effective January 1, 2026 and which changes also will adversely affect a portion of our product revenue in 2026.
+7 more — sign up free →
REMOVED
While our focus is primarily the United States market, we promote and sell our products internationally through direct sales representatives and stocking distribution partners in Europe, Canada, Mexico, South America, Australia, and certain Pacific region countries.
Our strategic focus is currently on digesting and growing the products and businesses we have acquired, producing our own stem cells, growth factor, amnio and synthetics biologics products, and continuing to focus on the following four key growth initiatives: (1) introduce new biologics products, including our Cortera Spinal Fixation System, viable bone matrix, OsteoVive Plus, and amniotic membrane allografts, SimpliGraft and SimpliMax ; (2) leverage our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions.
Recent Developments During the fourth quarter of 2024, we entered into a license agreement with a distributor granting an exclusive, nontransferable, non-sublicensable, royalty-bearing right and license to manufacture and commercialize in the United States our SimpliMax product and the trademarks associated therewith during the term of the agreement and subject to certain limitations as set forth therein.
Under the terms of the agreement, we received a one-time, up front, non-refundable, non-creditable cash payment of $1.5 million.
Beginning in 2025, we are entitled to quarterly royalty payments based on the volume of product sold by the distributor.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →